Milestone Scientific, Inc. · AMEX:MLSS
Milestone Scientific — Investor Presentation (August 2023)
17 slides from Milestone Scientific's investor presentation, August 2023
Slide 1: Investor Presentation August 2023
NYSE: MLSS Investor Presentation August 2023
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presenta+on contains forward-looking statements regarding the +ming and financial impact of Milestone's ability to implement its business plan, expected revenues, +ming of regulatory approvals and future success. These statements involve a number of risks and uncertain+es
Slide 3: Executive Summary
3 Executive Summary • Milestone Scientific Inc. is a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections • Rapidly expanding within the world-wide dental market • Leveraging track record in dental to aggressively expand into larger medi
Slide 4: THE STA - Single Tooth Anesthesia System
4 THE STA - Single Tooth Anesthesia System • FDA and CE marketing clearance in over 50 countries • Over 90 Million injections delivered to date • Key Opinion Leader recognition worldwide • Included in dental school programs as best practice • Aggressive domestic and international marketing initiativ
Slide 5: Direct Sales Model
5 Direct Sales Model • Launched January 2023 • Satisfied traction obtained • Margin improvement • Increased knowledge about customer ordering patterns • Potential for up-selling and customer reactivation
Slide 6: Why Enter the Epidural Market?
6 Why Enter the Epidural Market? Market Size • Epidural procedures are one of the fastest growing procedures in the US and worldwide • It is estimated that over 11M epidural procedures are performed each year in the US and over 30M worldwide • Over $5B spent annually on epidural injections in the US
Slide 7: Current Epidural Technology – the hypodermic syringe from 1860
7 Current Epidural Technology – the hypodermic syringe from 1860 The technique of "single-shot" lumbar epidural anesthesia was first developed in 1921 by Spanish military surgeon, Fidel Pagés, and hasn’t changed significantly since. 1946 “Modern” LOR Syringes Glass Loss of Resistance (LOR)
Slide 8: Listening to the Market – Addressing the Needs
8 Listening to the Market – Addressing the Needs • Placement of an epidural needle is difficult • Requires 60-90 placements before reaching an adequate skill level • 17% of failure rates are due to false loss of resistance (when the needle enters soft tissue or fatty tissue and the provider believes
Slide 9: Listening to the Market – Addressing the Needs
9 Listening to the Market – Addressing the Needs • Epidural Dural punctures are as high as 5+% • An Epidural puncture is when the Dura is breached and the needle enters the spinal canal, causing cerebral spinal fluid to leak resul]ng in headaches, pain, infec]on, and other morbidi]es cos]ng insurance
Slide 10: Cost Effectiveness Analysis of Two Labor Epidural Techniques
Cost EffecGveness Analysis of 10 Two Labor Epidural Techniques
Slide 11: A New Standard of Care in Anesthesia
11 A New Standard of Care in Anesthesia • Now with our patented CompuWave™ and CathCheck™ Verifica]on System features, anesthesiologists should be able to save significant ]me and ins]tu]ons should save significant costs • Correlates subjec]ve feel with objec]ve visual and audible verifica]on of pressur
Slide 12: New Features Added to CompuFlo Epidural Instrument
12 New Features Added to CompuFlo Epidural Instrument • With the addition of the patented CompuWave technology, we can now verify epidural placement AND confirm catheter placement in real time using the patients’ pulse • The waveform indicates whether or not the catheter is in the epidural space
Slide 13: Beyond Epidural: The Medical Opportunity
13 Beyond Epidural: The Medical Opportunity ü Now with our patented CompuWave™ technology the CompuFlo Catheter Epidural Instrument can now check catheters in 1-2 minutes not 20- Check 40 minutes. ü High-risk nature of procedure; 3 – 5 % of all epidurals; received 510(k) Thoracic FDA clearance for u
Slide 14: Recent Milestones
14 Recent Milestones ü Revenue for Q2 2023 increased 77% to $2.9 million due domestic and international growth • Growth was due in part to the early success of the new online portal • The portal provides a closer and more direct relationship with dentists, which contributed to a 178% increase in gro
Slide 15: Historical Revenue
15 Historical Revenue 12 $10.3 10 $8.8 8 $Millions 6 $5.4 4 2 0 2020 2021 2022 The decrease in 2022 revenue was driven by lower revenue from China and deliberate termination of a U.S. distributor agreement, which is expected to drive future revenue growth and higher margins. Dental division profitab
Slide 16: Key Statistics
Key Statistics 16 • Ticker: MLSS • Exchange: NYSE • Share Price (08/17/2023): $1.08 • Shares Outstanding (08/14/2023): 71.4 M • Market Cap: $77.1 M • Cash and Marketable Securities (6/30/2023): $5.7 M • Long-Term Debt (6/30/2023): $0 • Insider Ownership: 25.2%
Slide 17: Thank You
Thank You milestonescien*fic.com Investor Relations: Crescendo Communications, LLC NYSE: MLSS Email: mlss@crescendo-ir.com Website: https://www.milestonescientific.com/ Tel: 212-671-1020
Milestone Scientific — Investor Presentation (August 2023) on 6ix